论文信息 - Prodrugs of CL316243: a selective beta3-adrenergic receptor agonist for treating obesity and diabetes. - 字舞流文

Prodrugs of CL316243: a selective beta3-adrenergic receptor agonist for treating obesity and diabetes.

M. Malamas | Z. Chen | J. Ellingboe | A. Gilbert | I. Gunawan | V. Wong | A. Venkatesan | G. Francisco | K. Steiner | G. Grosu | E. Largis | J. Baker | F. Sum | K. Lim | J. Primeau | M. O'dell

[1] A. Reitz,et al. Pharmacological treatment of obesity: therapeutic strategies. , 1999, Journal of medicinal chemistry.

[2] F. Piétri-Rouxel,et al. Pharmacological characteristics and species‐related variations of β3‐adrenergic receptors , 1995, Fundamental & clinical pharmacology.

[3] J. Arch,et al. β3 and Atypical β‐Adrenoceptors , 1993 .

[4] M. Dutia,et al. Disodium (R,R)-5-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]-amino] propyl]-1,3-benzodioxole-2,2-dicarboxylate (CL 316,243). A potent beta-adrenergic agonist virtually specific for beta 3 receptors. A promising antidiabetic and antiobesity agent. , 1992, Journal of medicinal chemistry.

[5] Y. Yoshimura,et al. Preparation of 1-acyloxyethyl esters of 7-[2-(2-aminothiazol-4-yl)acetamido]-3-[[[1-(2-dimethylaminoe thy l)-1H-tetrazol-5-yl]thio]-methyl]ceph-3-em-4-carboxylic acid (cefotiam) and their oral absorption in mice. , 1986, The Journal of antibiotics.